Schedule a Vaccination | Reminder: Masks Are Still Required When Visiting
This is a Phase 1-2, multicenter, international, single-arm, open-label study designed to identify a recommended dose of bosutinib administered orally once daily in pediatric patients with newly diagnosed chronic phase Ph+ CML (ND CML) and pediatric patients with Ph+CML who have received at least on ...More
To learn more about available leukemia clinical trials, contact us at cancer@cchmc.org or 513-636-2799.